Aufman Associates Inc Apellis Pharmaceuticals, Inc. Transaction History

Aufman Associates Inc

  • $141 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$35.46 - $54.12 $1.66 Million - $2.53 Million
-46,751 Closed
0 $0
Q4 2021

Feb 09, 2022
SELL
$30.74 - $49.16 $211,829 - $338,761
-6,891 Reduced 12.85%
46,751 $2.21 Million
Q4 2019

Feb 06, 2020
BUY
$22.1 - $30.8 $1.19 Million - $1.65 Million
53,642 New
53,642 $1.64 Million

Others Institutions Holding APLS

# of Institutions
301
Shares Held
114M
Call Options Held
5.21M
Put Options Held
691K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.14B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Aufman Associates Inc Portfolio

Follow Aufman Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aufman Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Aufman Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email